Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation

Blood

Volumn 100, Issue 2, 2002, Pages 427-434

  Barnard, Dorothy R ^{a,b,c,d,e,f,g,h,i}   Lange, Beverley ^{a,b,c,d,e,f,g,h,i}   Alonzo, Todd A ^{a,b,c,d,e,f,g,h,i}   Buckley, Jonathan ^{a,b,c,d,e,f,g,h,i}   Kobrinsky, J Nathan ^{a,b,c,d,e,f,g,h,i}   Gold, Stuart ^{a,b,c,d,e,f,g,h,i}   Neudorf, Steven ^{a,b,c,d,e,f,g,h,i}   Sanders, Jean ^{a,b,c,d,e,f,g,h,i}   Burden, Laura ^{a,b,c,d,e,f,g,h,i}   Woods, William G ^{a,b,c,d,e,f,g,h,i}  

^a DALHOUSIE UNIVERSITY   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MeritCare Roger Maris Cancer Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; FEMALE; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; INFANT; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SPLENOMEGALY; SURVIVAL RATE; TRISOMY;

EID: 0037100301     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.2.427     Document Type: Article

References (55)

1. Chromosomal analysis of 63 cases of secondary nonlymphoid blood disorders: A cooperative study
2. Leukemia after therapy with alkylating agents for childhood cancer
3. Therapy-related leukemia and myelodysplastic syndrome
4. Therapy-related myelodysplastic syndromes
5. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
6. Therapy-related leukemia: Is the risk life-long and can we identify patients at greatest risk
7. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children
8. L-asparaginase may potential e the leukemogenic effect of the epipodophyllotoxins
9. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide
10. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
11. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
12. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
13. t(3;21)(q26);q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia
14. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
15. Therapy-related myeloid leukemia
16. Epipodophyllotoxin-related leukemia: Identification of a new subset of secondary leukemia
17. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
18. Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors
19. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy
20. Secondary acute myeloid leukemia following treatment with epipodophyllotoxins
21. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with UKCCSG regimens
22. Secondary leukemia (SL) or myelodysplastic leukemia (MDS) following therapy for Ewing's sarcoma (ES)
23. Timed-sequential induction therapy improves post-remission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
24. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group
25. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
26. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group
27. Proposals for the classification of the myelodysplastic syndromes
28. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Childrens Cancer Group
29. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome
30. On a test of whether one of two random variables is stochastically larger than the other
31. Nonparametric estimation from incomplete observations
32. Asymptomatically efficient rank invariant test procedures
33. Langerhans cell histiocytosis and etoposide: Risks vs. benefits
34. Myeloid neoplasia in children treated for solid tumours
35. Translocation (9;11)(p21;q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma
36. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation
37. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia
38. Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide
39. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors
40. Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Clinical studies
41. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis
42. Acute leukaemia in patients treated for Hodgkin's disease
43. Secondary acute myeloid leukemia in Hispanic children
44. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1
45. Childhood monosomy 7: Epidemiology, biology, and mechanistic implications
46. Treatment of therapy-related leukemia and myelodysplastic syndrome
47. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes
48. Therapy-related acute promyelocytic leukemia: A report of 16 cases
49. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH)
50. Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease
51. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia
52. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia
53. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French Society of bone marrow transplantation
54. Epipodophyllotoxin-related acute myeloid leukemia: A study of 35 cases
55. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia